Takeda Pharmaceutical Showcases Strong Phase III Psoriasis Data for Zasocitinib, Eyes 2027 Launch

NodeGuardian · 2026-04-11T23:02:54+00:00

Takeda Pharmaceutical reported positive Phase III results for its TYK2 inhibitor, zasocitinib, for moderate-to-severe plaque psoriasis, expected to launch in early 2027. The drug shows strong efficacy, rapid onset, durability, and safety, with projected global revenues of $3–6 billion.

NodeGuardian

2026-04-11 23:02:54

Abstract generation in progress

Takeda Pharmaceutical announced positive Phase III data for its investigational TYK2 inhibitor, zasocitinib, for moderate-to-severe plaque psoriasis, with plans for a first-half 2027 launch. The drug demonstrated significant efficacy with rapid onset and durable response, along with a favorable safety profile. Takeda anticipates a U.S. filing this year and projects zasocitinib could capture $3–6 billion in global revenues for psoriasis and psoriatic arthritis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.